MammaPrint® + BluePrint®

Every woman deserves a unique treatment strategy

For LN+ patients

MammaPrint® helps you to understand the metastatic potential of each tumor.
For patiens with node-positive (LN+) and node-negative (LN-) tumors.

LEARN MORE

Period or no period

MammaPrint® is effective to identify very low-risk tumors that would not benefit from chemotherapy in premenopausal women ≤50 years old. It helps to avoid overtreatment.

LEARN MORE

Latest news

Updated NCCN guidelines recognize MammaPrint® UltraLow Risk outcome for de-escalating treatment of patients with early breast cancer.

LEARN MORE

MammaPrint® + BluePrint® together help address the complexity of early breast cancer

Are you receiving the complete information to make timely decisions about the optimal treatment?

1 in 8 women will be diagnosed with breast cancer in her lifetime.

Treatment plan information is crucial to improving patient outcomes and management.

More than 33,000 new cases of breast cancer in Spain in 2019

What do we offer you as valuable information for decision making?

MammaPrint®

Relapse risk test

MammaPrint®, 70-gene breast cancer relapse test, is the first FDA approved and CE marked test, supported by peer-reviewed data from prospective studies included in major treatment guidelines.

  • Study genes involved in each study of the metastatic cascade
  • Results are independent and complementary to standard IHC/FISH tests
  • MammaPrint® allows to predict the risk of relapse of the disease
  • Helps personalize treatment to avoid treatments that are unnecessary

BluePrint®

Functional molecular subtyping

BluePrint®, the 80-gene molecular substaging test, goes beyond the surface cells, evaluating the underlying biology that drives tumor growth.

  • BluePrint® identifies the underlying biology driving tumor growth and enables more accurate molecular substaging to be identified
  • Approximately 1 in 5 pathologically RH+ women are reclassified to Basal Type-High Risk tumors

Learn more about MammaPrint® and BluePrint®

Patient cases

How do we minimize under and over treatment in the pre-operative setting?

Case to study

Patient presents a large tumor

Clinical features
  • 61-year-old patient
  • Invasive ductal tumor of 4,5cm
  • ER+ 90%, 80% by IHC
    HER2 negative by IHC and FISH
  • Clinically negative node
  • Grade 2
Genomic results
  • BluePrint Luminal A-Type
  • MammaPrint Low Risk

How do we minimize under and over treatment in the pre-operative setting?

Case to study

Patient presents a Small RH+ Tumor

The patient is going on vacation for 2 months and would like to postpone her cancer treatment if possible

Clinical features
  • 31-year-old patient
  • 1,8cm tumor
  • ER+ 90%, PR- by IHC
  • HER2 negative by IHC and FISH
  • Clinically negative node
  • Grade 2
Genomic results
  • BluePrint Basal-Type
  • MammaPrint High Risk

How do we minimize under and over treatment in the pre-operative setting?

Case to study

Patient presents an RH+ Tumor

Patient has side effects and wants to discontinue endocrine therapy

Clinical features
  • 57-year-old patient
  • 2,1cm tumor
  • ER+ 100%, RP+ 85% by IHC
  • HER2 negative by IHC and FISH
  • Clinically negative node
  • Grade 1
Genomic results
  • BluePrint Luminal A-Type
  • MammaPrint Ultralow Risk

How do we minimize under and over treatment in the pre-operative setting?

Case to study

LN+ breast cancer patient

Clinical features
  • 55-year-old patient
  • 3cm tumor
  • ER+ 90%, RP+ 90% by IHC
  • HER2 negative by IHC and FISH
  • Positive node
  • Grade 2
Genomic results
  • BluePrint Luminal A-Type
  • MammaPrint Low Risk

How to request it?

Request MammaPrint® + BluePrint®

Every woman deserves a unique treatment strategy

Apply now
Download brochure